Eritoran insight for influenza treatment

A University of Maryland team has used a toll-like receptor 4 antagonist to treat influenza in mice. The results provide a repurposing opportunity for Eisai's TLR4 blocker Eritoran, originally developed for sepsis and could extend to treating respiratory infections beyond the flu.

Detalles Bibliográficos
Autor principal: Baas, Tracey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149081/
http://dx.doi.org/10.1038/scibx.2013.453
Descripción
Sumario:A University of Maryland team has used a toll-like receptor 4 antagonist to treat influenza in mice. The results provide a repurposing opportunity for Eisai's TLR4 blocker Eritoran, originally developed for sepsis and could extend to treating respiratory infections beyond the flu.

Ejemplares similares